Sign In
Buy ALT
$2.87
-0.0300 (-1.03%)
At Close: Jun 03, 2026
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023
03:00pm, Wednesday, 22'nd Mar 2023 Benzinga
Upgrades
Clarkson Capital Markets upgraded the previous rating for Transocean Ltd (NYSE:RIG) from Neutral to Buy. In the fourth quarter, Transocean showed an EPS of $0.49, compared to $0.19 from the y
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
01:00pm, Wednesday, 22'nd Mar 2023
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
09:55am, Wednesday, 22'nd Mar 2023 The Motley Fool
It's not the end of the story for this once high-flying biotech stock.
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
05:55am, Wednesday, 22'nd Mar 2023
Analysts had lofty expectations for Altimmune and the prospects for pemvidutide in treating obesity. However, pemvidutide's side effects in a phase 2 study were concerning.
Nasdaq Up Over 100 Points; Crude Oil Rises 2%
06:31pm, Tuesday, 21'st Mar 2023 Benzinga
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Tuesday.
The Dow traded up 0.41% to 32,376.61 while the NASDAQ rose 1.05% to 11,798.39. T
Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
04:53pm, Tuesday, 21'st Mar 2023 Benzinga
Gainers
U.S. Xpress Enterprises, Inc. (NYSE: USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.
Impac Mortgage Holdings, Inc. (NYSE:
Gold Drops Over 1%; Existing Home Sales Surge In February
04:05pm, Tuesday, 21'st Mar 2023 Benzinga
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Tuesday.
The Dow traded up 0.65% to 32,455.57 while the NASDAQ rose 0.57% to 11,741.91. The S&P 500
US Stocks Open Higher; Nasdaq Jumps Over 100 Points
02:08pm, Tuesday, 21'st Mar 2023 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.90% to 32,535.25 while the NASDAQ rose 1.0
Why Is Altimmune (ALT) Stock Down 67% Today?
10:12am, Tuesday, 21'st Mar 2023
Altimmune (NASDAQ: ALT ) stock is losing value on Tuesday after the company released results from a clinical trial. That trial has to do with the company's treatment for obesity.
Analyst Ratings for Altimmune
01:00pm, Thursday, 09'th Mar 2023 Benzinga
Altimmune (NASDAQ:ALT) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
0
Last 30D
1
0
Altimmune's Peptide-Based Therapies Offer Substantial Opportunity
03:09am, Thursday, 23'rd Feb 2023
Altimmune is a pioneer in creating peptide-based therapies for obesity and liver disease, with a unique approach to product development. Altimmune's R&D expenses have dropped year-on-year due to the d
Altimmune: Potential Dual Action For Pemvidutide In Obesity, NASH
07:35pm, Tuesday, 21'st Feb 2023
Altimmune has exposure to promising growth areas of obesity and non-alcoholic liver disease treatment. Upcoming trial data and proof of concept work for its pemvidutide compound is key to see the stoc
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
12:30pm, Tuesday, 21'st Feb 2023 GlobeNewswire Inc.
GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2
Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
07:30am, Tuesday, 21'st Feb 2023
GAITHERSBURG, Md., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 202
Why Altimmune, Foghorn Therapeutics, and Precigen Shares Crashed This Week
06:49pm, Thursday, 16'th Feb 2023 The Motley Fool
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.
